Chroma Therapeutics - Gilde Healthcare

Chroma Therapeutics


Abingdon, UK

Cancer Therapeutics
Since: 2004

Chroma Therapeutics discovers and develops novel small-molecule drugs for the treatment of common cancers and inflammatory disorders.

Gilde joined the company as one of its first investors. The company has since advanced its lead product Tosedostat®, for leukemia, to the final development stage. It has also built a product pipeline of new inflammation therapies using its proprietary cell accumulation approach, which targets the nucleus of a cell. In 2009 it began to partner with GlaxoSmithKline (GSK). Chroma Therapeutics is based in Oxford, UK.

More Chroma Therapeutics news

Chroma Therapeutics – Tosedostat OPAL Study in Acute Myeloid Leukaemia Published in the Lancet

Chroma Therapeutics Advances Novel Targeted Agent towards Clinical Development; Receives Milestone

Chroma Therapeutics enters collaboration with Cell Therapeutics Inc

Chroma Therapeutics signs $1 billion deal with GlaxoSmithKline

Chroma Therapeutics completes £15 million Series D financing

CHROMA announces Positive Phase II Efficacy Data for Novel Cancer Therapy Tosedostat